Close this search box

Phone
+44 7384 789152
Email
mdominikfischer@gmail.com
Location
Oxford, United Kingdom

Ophthalmology advisory for industry and healthcare

Clinical authority that moves decisions forward

Professor Dominik Fischer advises biotech, pharma, investors and healthcare organisations on retinal disease, gene and cell therapy and the translation of science into treatments that reach patients.

Direct access to one of the field’s leading surgeon-scientists, focused on the questions that carry real commercial and clinical weight.

Discuss an engagement

See how he can help

Where deep science meets commercial judgement

Companies developing sight-saving therapies face the same hard questions again and again. Is the science sound. Will the trial design hold up. Does the asset justify the investment. How will regulators and clinicians respond. Professor Fischer has sat on every side of those questions, as a surgeon, a chief investigator, a peer reviewer and an adviser to the companies bringing these treatments to market. His input is designed to sharpen decisions, not pad them out.

Advisory boards and strategic counsel

Ongoing input on programmes, pipelines and positioning, informed by a clear view of where the field is heading.

Expert consultation

Focused, senior-level answers to specific clinical and scientific questions, without the noise.

Scientific and clinical due diligence

Independent assessment of assets, programmes and claims for investors and acquirers.

Clinical development and trial strategy

Trial design, endpoints and development planning grounded in real surgical and regulatory experience.

Regulatory and market access advisory

Perspective shaped by direct work with trials, regulators and health systems.

Medical education and scientific communication

Authoritative faculty and content for a professional clinical audience.

Explore engagement types

A track record built on genuine firsts

Professor Fischer has led work that had never been done before, including the world’s first gene therapy targeting cones and the first global post-approval safety study for an ocular gene therapy. When he assesses a programme, he does so from the position of someone who has helped define the field rather than observe it.

Senior input, without the overhead

Direct access

You work with Professor Fischer himself, not a team briefed on his behalf.

Framed around your decision

Engagements start from the question you actually need answered.

Honest and independent

Clear views, including the ones you might not want to hear.

Discreet and selective

He takes on a limited number of engagements and treats every one in confidence.

Invited lectures worldwide

0 +

Peer-reviewed publications

0 +

Citations, h-index 29

0 +

International awards

0 +

Selected clients and partners

Trusted by leaders in the field

Professor Fischer has advised or consulted for organisations across pharma, biotech, investment and healthcare, including Novartis, Roche, Bayer, Biogen, Janssen Research and Development, RegenxBio, Adverum, Atsena Therapeutics, Frontera Therapeutics, Sparing Vision, Arctos Medical, Mogrify, Cambridge Consultants and Retina International.

Start a conversation

Bring him the question that matters

If you are weighing a decision where senior clinical and scientific judgement would change the outcome, start a conversation.